

COVID-19 Vaccine Consent & Questionnaire - Universal

Date	Recipient temperatu		ature Recipient		: weight					
		Patien	t Information							
Name (please print)			Parent/Guardian (if applicable please print)							
DOB	Age	Gender	Preferred Language							
Address			City Stat	e Zi _l)					
Phone Number			Email Address							
Ethnicity (circle one)										
Hispanic	Not Hi	spanic or Latino	Unknov	vn	De	clined				
Race (circle one)										
American Indian or	Alaska Nativ	e Asian	Native	Hawaiian/Ot	n/Other Pacific Islander					
Black or African Am	erican	White	Other Race Declined							
The following question today. If you answer means additional que explain it.	"yes" to any estions may	us determine if the question, it does	not necessarily m	ou should r	ould not our healtl	be vaccin hcare prov	ated. It just			
1. Are you feeling si	ick today?				Yes	No				
2. Have you ever received a dose of COVID-19 va			cine?		Yes	No	Unknown			
•	•	luct did you receive □ Janssen (Johnso		Another Pr	oduct: _					
EpiPen® or that ca	e a severe alle used you to go	reaction to: rgic reaction [e.g., ar to the hospital. It w including wheezing.)	ould also include ar							
A component	t of the COV	ID-19 vaccine inclu	ding either of the	following:						
· · · · · · · · · · · · · · · · · · ·), which is found in		Yes	No	Unknown				
•	, which is for nous steroids	und in some vaccin	es, film coated tal	blets,	Yes	No	Unknown			
					.,					

COVID-19 Vaccine Consent & Questionnaire - Universal



COVID-1 (This wou with epin	u ever had an allergic re 19 vaccine) or an injectal Ild include a severe allergicre ephrine EpiPen® or that cause eaction that caused hives, swe	Yes	No	Unknown						
•	ou have a health condition ou moderately or severe	Yes	No	Unknown						
If yes, check	k all that apply to you:									
	eceiving active cancer or									
			medicine to suppress the immu	•						
	☐ Received a stem cell transplant within the last 2 years or are taking medicine to suppress the immune									
•	system Moderate to severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)									
☐ Active 1	treatment with high-dos	e corticostero	ids or other drugs (methotrexa	te, azathi	oprine, le	flunomide,				
	adalimumab, rituximab, tacrolimus, cyclosporine, mycophenolate) that may suppress your immune									
respons	se									
6. Have you received hematopoietic cell transplant (HCT) or CAR-T-cell Yes No Unk										
•	es since receiving COVID									
	Additional CDC Screening Questions									
	Check all that apply to you:									
	☐ Have a history of myocarditis or pericarditis ☐ Have a history of thrombosis with ☐ Have a history of Multisystem Inflammatory Syndrome thrombocytopenia syndrome (TTS)									
	Thave a history of Mattisystem inhaminatory Syndrome									
•	(CDC)									
	☐ History of an immune-mediated syndrome defined by thrombosis and thrombocytopenia, such as heparin- ☐ Have a history of COVID-19 disease within									
induced thrombocytopenia (HIT) the past 3 months.										
Primary Series Vaccine Information										
Please complete this section if you have already received a previous COVID-19 vaccine dose(s).										
Primary series vaccine for Pfizer (ages 5+) and Moderna (ages 18+) is considered 2 (two) doses and for										
Janssen (ages 18+) is considered 1 (one) dose. Primary series vaccine for Pfizer (6 months – 4) is considered 3										
(three) doses and Moderna (6 months – 5) is considered 2 (two) doses.										
${f @}$ Please see additional information regarding immunocompromised individuals on the following page.										
Date of			Vaccine administered: ☐ Pfi	izer 🗆 M	oderna □	l Janssen				
1 st dose	/ / D Hakaayaa									
			•							
Date of Vaccine administered: Pfizer Moderna										
2 nd dose			☐ Another product:							
Date of			Vaccine administered: ☐ Pfi	izer						
3 rd dose	//	☐ Unknown	☐ Another product:							

COVID-19 Vaccine Consent & Questionnaire - Universal

	Immune	ncompromised Ad	Iditional Primary Serie	as Information						
	sidered imm	unocompromised, you	•	nal primary series dose of the Pfizer						
Date of		□ Unknown	Vaccine administered: ☐ Another product:	☐ Pfizer ☐ Moderna						
COVID-19 Vaccine Bivalent Booster Shot Information Pfizer, Moderna, & Janssen*										
If you received primary series: Pfizer-BioNTech (Comirnaty)	rimary series: fizer-BioNTech Comirnaty) Group: At least 2 months after primary COVID vaccinat For immunocomprom		fter completing your cination series	Which booster can you get: Ages 5-11 can get a Pfizer Bivalent booster Ages 6-11 can get a Pfizer Bivalent or Moderna Bivalent booster Which booster can you get: Ages 12+ can get a Pfizer Bivalent or Moderna Bivalent booster						
If you received primary series: Moderna (Spikevax)	Age Group: Ages 5+	When to get a booster: At least 2 months after completing your primary COVID vaccination series For immunocompromised, at least 2 months after additional primary series dose		Which booster can you get: Ages 5-11 can get a Pfizer Bivalent booster Ages 6-11 can get a Pfizer Bivalent or Moderna Bivalent booster Which booster can you get: Ages 12+ can get a Pfizer Bivalent or Moderna Bivalent booster						
If you received primary series: Janssen (Johnson & Johnson) *The CDC recomm (Janssen) COVID-		primary COVID vaco For immunocomp months after add dose	fter completing your cination promised, at least 2 ditional primary series	Which booster can you get: Ages 18+ can get Pfizer Bivalent or Moderna Bivalent booster D-19 vaccine over Johnson & Johnson's						
By signing this for	m, I attest th		including additional doses	ne, as stated by the CDC, since for immunocompromised people.						

Emergency Use Authorization

The FDA has made the COVID-19 vaccine available under an emergency use authorization (EUA). The EUA is used when circumstances exist to justify the emergency use of drugs and biological products during an emergency, such as a COVID-19 pandemic. This vaccine has not completed the same type of review as an FDA-approved or cleared product. However, the FDA's decision to make the vaccine available under an EUA is based on the existence of a public health emergency and the totality of scientific evidence available, showing that known and potential benefits of the vaccine outweigh the known and potential risks.

Consent for Services

I have been provided with information to access the EUA and/or Fact Sheet for the corresponding COVID-19 vaccine(s) that I am receiving. I understand that the Pfizer and Moderna vaccine require two (2) or three (3) doses dependent on age and immunocompromised people, and the Janssen vaccine requires one (1) dose (two (2) doses for immunocompromised people) to be administered in order for it to be effective. I have read the information provided about the vaccine I am to receive. I have had the chance to ask questions that were answered to my satisfaction, I understand the benefits and risks of vaccination and I voluntarily assume full responsibility for any reactions that may result. I understand that I should remain in the post vaccine waiting area for at least 15 minutes (30 minutes if necessary) after the vaccination to be monitored for any potential adverse reactions. I understand that if I experience side effects that I should do the following: contact the VNA Health Care or call 911. I request that the vaccine be given to me or to the person for whom I am authorized to make this request.

Disclosure of Records

Date

I understand that VNA Health Care may be required to or may voluntarily disclose all my health information needed to report administration of vaccine and/or other public health purposes, including reporting to applicable vaccine registries.

Consent for Communication

y signing below, I agree to receive future communications from VNA Health Care via email, phone call or text nessage. If you wish not to receive emails, phone calls or text messages from VNA Health Care.							
Please initial here to opt out							
Recipient/Guardian Signature	-						
Print Name	-						
Relationship to patient, other than recipient							

Time

COVID-19 Vaccine Consent & Questionnaire - Universal

Vaccine Administration Office Use Only											
Vaccine Location (CIRCLE ONE)											
VNA-Highland	VNA-Indian VNA-Villa VNA-Wing VNA-Mona Kea VNA-Mobile Clinic										
VNA-Bensenville	VNA-B	VNA-Bolingbrook VNA-Romeoville VNA-Joliet VNA-Offsite Clinic									
Primary Series (CIRCLE DOSE)											
	Pfizer-BioNTech		Pfizer- BioNTech (Comirnaty)		Moderna		Modern	Moderna (Spikevax)		Janssen (Johnson & Johnson)	
Age Range	6 month	5-11	12	<u>:</u> +	6 mont	months -5		6-11 12+		18+	
First Dose	0.2 mL	0.2 mL	0.3	mL	0.25 m	0.25 mL		0.5 m	nL	0.5 mL	
Second Dose	0.2 mL	0.2 mL	0.3 mL		0.25 m	0.25 mL 0.5 mL		0.5 mL		N/A	
Third Dose	0.2 mL	N/A	N/	'A	N/A		N/A	N/A		N/A	
Third Dose Immunocompromised	N/A	0.2 mL	0.3 mL		N/A		0.5 mL	0.5 m	nL	N/A	
		В		ccine (CI		OSE)			1		
	Pfizer-B Biva	ioNTech Ilent	Pfizer-BioNTech (Comirnaty) Bivalent		Moderna (Spikevax) Bivalent)		Janssen (Johnson & Johnson)		
	Ages	Ages 5-11 Ages 12+ Ages 6-			Age	Ages 18+					
Primary Series	Dose	Interval	Dose	Interva	l Do	se	Dose	Interval	Dose		Interval
Pfizer	0.2 mL	2 months	0.3 mL	2 month	ns 0.25	mL	0.5 mL	2 months	0.5 mL		5 months
PfizerImmunocompromised	0.2 mL	2 months	0.3 mL	2 month	ns 0.25	mL	0.5 mL	2 months	0.5 mL		3 months
Moderna	0.2 mL	2 months	0.3 mL	0.3 mL 2 mont		mL	0.5 mL	2 months	0.5 m	١L	5 months
ModernaImmunocompromised	0.2 mL	2 months	0.3 mL	2 month	ns 0.25	mL	0.5 mL	2 months	0.5 mL		3 months
Janssen	N/A	N/A	0.3 mL	2 month	ns 0.25	0.25 mL		2 months	0.5 mL		2 months
JanssenImmunocompromised	N/A	N/A	0.3 mL	2 month	ns 0.25	mL	0.5 mL	2 months	0.5 mL		2 months
Administration Site (circle one) Left Deltoid Right Deltoid Left Thigh Right Thigh											
Manufacturer Lot Number: Expiration Date:											
Vaccine Administrator Signature											